GlassScriptPhysician profile
Vincent A Tomasuolo
NPI 1053317701
$2,077.36
in general payments reported to CMS, 2019-2025
23 companies · $14.72 in 2025
The $14.72 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,222 · 2020: $248 · 2021: $246 · 2022: $116 · 2023: $150 · 2024: $80.38 · 2025: $14.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $573.61 | 2019-2024 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $305.00 | 2019-2023 | Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.57 | 2019-2021 | |
| Inspire Medical Systems, INC. | $117.34 | 2023 | Inspire |
| Philips North America LLC | $117.02 | 2019-2020 | |
| Mylan Specialty L.P. | $113.93 | 2019-2023 | Yupelri |
| Grifols USA, LLC | $111.78 | 2019-2024 | Prolastin-C Liquid |
| Genzyme Corporation | $110.21 | 2019 | |
| Sunovion Pharmaceuticals INC. | $58.70 | 2019 | |
| Ceribell, INC. | $48.70 | 2024 | Pocket Eeg Device |
| Teva Pharmaceuticals USA, INC. | $42.37 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $39.93 | 2019 | |
| Allergan, INC. | $39.81 | 2019 | |
| Vapotherm INC | $31.56 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $25.57 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.09 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.80 | 2019 | |
| Fisher & Paykel Healthcare INC | $14.72 | 2025 | Fisher & Paykel Healthcare |
| Amgen INC. | $14.45 | 2019 | |
| Apria Healthcare LLC | $13.48 | 2021 | |
| Celgene Corporation | $13.46 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2020 | |
| United Therapeutics Corporation | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Tomasuolo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.